Literature DB >> 26525064

Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.

Lucia Barbieri1, Monica Verdoia1, Paolo Marino1, Harry Suryapranata2, Giuseppe De Luca3.   

Abstract

BACKGROUND: Contrast-induced nephropathy is a common complication of procedures that are likely to use contrast media. The identification of high-risk patients and preventive optimal hydration are key measures to reduce the incidence of contrast-induced nephropathy. The aim of this study was to evaluate the role of the contrast volume to creatinine clearance ratio (V/CrCl) in the prediction of contrast-induced nephropathy after coronary angiography or percutaneous coronary intervention.
METHODS: Our population consisted of 2308 consecutive patients undergoing coronary angiography and/or percutaneous coronary intervention. The risk of contrast-induced nephropathy was evaluated across quartiles of the V/CrCl. Receiver operating characteristic curves were used to identify the best predictive value. Contrast-induced nephropathy was defined as an absolute increase of 0.5 mg/dL or a relative increase of >25% in creatinine levels 24-48 hours after the procedure.
RESULTS: The total incidence of contrast-induced nephropathy was 12.2% and was significantly higher in the fourth quartile (first quartile 8.8%, second quartile 8.9%, third quartile 11.6% and fourth quartile 19.4%; P < 0.001). Using receiver operating characteristic curves we identified V/CrCl ≥ 6.15 as the best discriminant value for the prediction of contrast-induced nephropathy, which occurred in 25.1% of patients with V/CrCl ≥ 6.15 versus 9.7% in patients with V/CrCl < 6.15. These results were also confirmed at multivariate analysis after correction for all baseline confounders (adjusted odds ratio (AOR) (95% confidence interval (CI)) 1.81 (1.19-2.76); P = 0.005). The association between V/CrCl > 6.15 and an increased risk of contrast-induced nephropathy was confirmed among diabetic (11% vs. 27.7%; p P < 0.001) and non-diabetic patients (8.9% vs. 23%; Pp < 0.001), also after correction for all baseline confounders.
CONCLUSIONS: This is one of the largest studies evaluating the association between the V/CrCl ratio and the risk of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous coronary intervention. We found that a V/CrCl ratio >6.15 was independently associated with an increased risk of contrast-induced nephropathy. © The European Society of Cardiology 2015.

Entities:  

Keywords:  Coronary intervention; acute renal failure; contrast media

Mesh:

Substances:

Year:  2015        PMID: 26525064     DOI: 10.1177/2047487315614493

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  11 in total

1.  Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Authors:  Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

2.  Predictors and Outcomes of Postcontrast Acute Kidney Injury after Endovascular Renal Artery Intervention.

Authors:  Edwin A Takahashi; David F Kallmes; Chad J Fleming; Robert J McDonald; Michael A McKusick; Haraldur Bjarnason; William S Harmsen; Sanjay Misra
Journal:  J Vasc Interv Radiol       Date:  2017-09-22       Impact factor: 3.464

3.  [Acute kidney injury and renal replacement therapy in victims from out-of-hospital cardiac arrest with administration of contrast agent].

Authors:  Martin Christ; Katharina Isabel Auenmüller; Scharbanu Amirie; Michael Brand; Benjamin Michel Sasko; Hans-Joachim Trappe
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-12-15

4.  Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.

Authors:  Ali O Malik; Amit Amin; Kevin Kennedy; Mohammed Qintar; Ali Shafiq; Roxana Mehran; John A Spertus
Journal:  Am Heart J       Date:  2021-01-25       Impact factor: 4.749

5.  Risk factors for acute renal injury caused by contrast media after percutaneous coronary intervention and coronary angiography: A protocol for systematic review and meta-analysis.

Authors:  Junhuan Hou; Guanghua Cao; Junling Liu; Li Cai; Li Zhao; Xue Li
Journal:  Medicine (Baltimore)       Date:  2022-02-18       Impact factor: 1.817

Review 6.  Radiographic and magnetic resonances contrast agents: Essentials and tips for safe practices.

Authors:  Mohamed R Nouh; Mohamed A El-Shazly
Journal:  World J Radiol       Date:  2017-09-28

7.  The Negative Effect of Mean Perfusion Pressure on the Development of Acute Kidney Injury after Transcatheter Aortic Valve Implantation.

Authors:  Ilker Gül; Levent Cerit; Bihter Senturk; Mustafa Zungur; Mustafa Beyazıt Alkan; Hatice Kemal; Zeynep Cerit; Belma Yaman; Songul Usalp; Hamza Duygu
Journal:  Braz J Cardiovasc Surg       Date:  2018 Nov-Dec

8.  Early clinical experiences with a novel contrast volume reduction system during invasive coronary angiography.

Authors:  Raphael R Bruno; Amir M Nia; Georg Wolff; Ralf Erkens; Malte Kelm; Ralf Westenfeld; Christian Jung
Journal:  Int J Cardiol Heart Vasc       Date:  2019-05-15

9.  Predictors of contrast induced nephropathy and the applicability of the Mehran risk score in high risk patients undergoing coronary angioplasty-A study from a tertiary care center in South India.

Authors:  Sanjai Pattu Valappil; Sivaprasad Kunjukrishnapillai; Mathew Iype; Alummoottil George Koshy; Sunitha Viswanathan; Prabha Nini Gupta; Radhakrishnan Vellikatu Velayudhan; Faeez Mohamad Ali
Journal:  Indian Heart J       Date:  2017-08-26

10.  Inhibiting PKCβ2 protects HK-2 cells against meglumine diatrizoate and AGEs-induced apoptosis and autophagy.

Authors:  Wenbing Jiang; Wei Zhao; Fanhao Ye; Shiwei Huang; Youyang Wu; Hao Chen; Rui Zhou; Guosheng Fu
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.